Bharat Parenterals credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY23Mar 2023	FY22Mar 2022

	6.9	9.7
	−0.5	−6.3
	0.04×	0.06×
	0.00×	−0.04×
	0.32×	0.35×
	−0.03×	−0.23×
	7.10×	24.04×
	3.5%	5.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BPLPHARMA₹1,912.60

Bharat Parenterals Limited

· Pharma & Health

₹ CrorePeersJENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOCMcap ₹1,105 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023
Total Debt	9.7	6.9
Net Debt	-6.3	-0.5
Total Debt/Equity	0.06	0.04
Net Debt/Equity	-0.04	0.00
Total Debt/EBITDA	0.35	0.32
Net Debt/EBITDA	-0.23	-0.03
Interest Coverage (EBIT/Interest)	24.04	7.10
Total Debt/Total Capital %	5.54	3.48

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.